Legal fees are stacking up in CRISPR dispute
$10.9 million. That is how much Editas Medicine has spent so far this year on legal fees incurred by the Broad Institute and Harvard. Most of that money has been spent to defend CRISPR invention patents held by Editas co-founder and Broad scientist Feng Zhang.
Sharon Begley writes: “Law professor Jacob Sherkow of New York Law School, an expert in intellectual property law who has been following the CRISPR fight closely, called the legal bill “a lot even by patent litigation standards” He had expected the dispute, “from soup to nuts,” to come in at less than $10 million a side. (The University of California, Berkeley has challenged CRISPR patents issued to the Broad and Harvard University.)”
Read the rest of the STAT News article here.